P2, N=189, Completed, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026

1 day ago

Trial completion • Trial completion date • Trial primary completion date

Herceptin (trastuzumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery (clinicaltrials.gov)

P2, N=164, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

1 day ago

Trial completion date • Trial primary completion date

gemcitabine • oxaliplatin • dexamethasone • dexamethasone injection

Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatmentafter Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)Patients IMMUNOSTAR Trial - GOIRC-02-2024 (2024-519798-20-00)

P1/2, N=270, Recruiting, G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica | Not yet recruiting --> Recruiting

1 day ago

Enrollment open • pMMR

MSI (Microsatellite instability)

capecitabine • oxaliplatin • Jemperli (dostarlimab-gxly)

SHIELD: Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy (clinicaltrials.gov)

P2, N=20, Recruiting, Xiujuan Qu

1 day ago

New P2 trial

HER-2 (Human epidermal growth factor receptor 2)

HER-2 overexpression

Herceptin (trastuzumab) • oxaliplatin • Hetronifly (serplulimab)

CBC3T-3: a novel patient-derived cisplatin-resistant distal cholangiocarcinoma cell line harboring multiple TP53 missense mutations. (PubMed, Hum Cell)

Drug sensitivity analysis revealed that, compared with TFK-1 cells, CBC3T-3 cells presented significantly greater responses to paclitaxel, gemcitabine, and oxaliplatin but relatively poor responses to 5-FU and cisplatin...The establishment of the CBC3T-3 cell line enhances the research toolkit for dCCA. Its genomic characteristics and functional plasticity provide a reliable preclinical tumor model for developing precision therapies and investigating drug resistance mechanisms.

2 days ago

Preclinical • Journal • Tumor mutational burden

TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden)

TP53 mutation

cisplatin • gemcitabine • paclitaxel • 5-fluorouracil • oxaliplatin

Visceral crisis in HER2-positive, AFP-producing gastric cancer. (PubMed, BMJ Case Rep)

Our patient presented with a visceral crisis denoted by impending liver failure, prompting the urgent initiation of first-line systemic therapy with fluorouracil, leucovorin, oxaliplatin and trastuzumab. This resulted in rapid clinical improvement, normalisation of liver function tests and tumour markers, and radiographic response with approximately 50% reduction in hepatic metastatic disease burden. This case underscores the aggressive behaviour and rarity of HER2-positive, AFP-producing gastric cancer, highlighting the critical need for prompt diagnosis and initiation of systemic therapy.

2 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • AFP (Alpha-fetoprotein)

HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression

Herceptin (trastuzumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium

Mass cytometry uncovers distinct blood myeloid phenotypes linked to clinical responses during gastric cancer chemoimmunotherapy. (PubMed, Cancer Immunol Immunother)

We aimed to explore circulating immune cells and elucidate the mechanisms underlying the therapeutic effects of pembrolizumab and capecitabine/oxaliplatin (XELOX) in patients with metastatic GC. Our results elucidate the serial immunological landscape underpinning favorable responses to first-line ICI plus chemotherapy in patients with gastric cancer. Early distinct changes in blood myeloid cells during chemotherapy can be used to assess clinical response.

2 days ago

Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • NCAM1 (Neural cell adhesion molecule 1) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • CCL3 (C-C Motif Chemokine Ligand 3) • ITGAX (Integrin Subunit Alpha X)

Keytruda (pembrolizumab) • capecitabine • oxaliplatin

JS212 Combination Therapies in Metastatic Colorectal Cancer (clinicaltrials.gov)

P2, N=80, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.

2 days ago

New P2 trial

capecitabine • oxaliplatin

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer (clinicaltrials.gov)

P2, N=134, Not yet recruiting, Fudan University

2 days ago

New P2 trial

Erbitux (cetuximab) • capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701) • CS1002 (ipilimumab biosimilar) • HRS-4642

Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases (clinicaltrials.gov)